Given the primary role of increased hepatic gluconeogenesis in the pathogenesis of hyperglycemia in insulin resistance and type 2 diabetes, new drugs aimed at targeting OGG1 specifically to mitochondria may propose a novel form of treatment for metabolic disease. Here, OGG1 is linked to metabolic disease.